Steve Jobs: Brilliant Tyrant

Speculation about Apple boss has crossed the line

(NEWSER) - Speculation about the state of Steve Jobs' health is reaching fever pitch, and the scramble to know more is over the top, Tom Krazit writes in CNET. Shareholders, concerned by the Apple CEO's recent weight loss and the fact that he once had pancreatic cancer, are calling for full disclosure. But as long as it's not a liability to the firm, Jobs' health should be a private matter, Krazit insists. More»

(AP) - Apple co-founder and CEO Steve Jobs is back at work after a five-and-a-half-month medical leave, during which he received a liver transplant. Jobs, 54, is working from Apple's Cupertino, Calif., headquarters "a few days a week" and working from home the remaining days, an Apple spokesman said today. More»

Apple board rebuffs requests for updates on CEO's health

(NEWSER) - Apple shareholders left an annual meeting today upset at the company’s board for staying mum about CEO Steve Jobs’ health, the Wall Street Journal reports. Considered the company’s chief innovator, Jobs rattled Apple’s stock price last month with news that treatment for a hormone imbalance would sideline him until June. The board said Jobs remains deeply involved in company strategy. More»

Report that CEO had heart attack is false, company says

(NEWSER) - Apple again today was forced to quash rumors about the health of CEO Steve Jobs, refuting a report that the CEO had suffered a “major heart attack,” Bloomberg reports. Shares fell as much as 5.4% following a post on CNN’s citizen-journalist iReport site, but have since rebounded. Jobs’ health has been an issue since a bout with pancreatic cancer in 2004. More»

Tentative $14M deal will put an array of state and federal lawsuits to rest

(NEWSER) - Apple CEO Steve Jobs and several current and former execs have reached a tentative settlement on a shareholder lawsuit alleging they backdated stock options to boost their pay, the Wall Street Journal reports. Apple will receive $14 million in the deal, which would end a series of state and federal suits that followed the company’s admission of improper grants in 1997-2002. More»